SOPHiA GENETICS (NASDAQ:SOPH) is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.
The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders. By harmonizing data from multiple assay types—such as whole-exome sequencing, targeted gene panels and radiomic features—SOPHiA GENETICS enables researchers and clinicians to identify genetic variants, predict disease progression and guide personalized treatment decisions. The company also offers software modules for digital pathology, transcriptomics and copy-number variation analysis.
SOPHiA GENETICS serves a global customer base spanning more than 70 countries across North America, Europe, Latin America and Asia-Pacific. Its network includes academic medical centers, diagnostic laboratories and pharmaceutical firms engaged in clinical trials. Through strategic partnerships and a growing user community, the company continues to expand its data repository, improving the robustness of its AI-driven analytics and facilitating collaborative research efforts in precision medicine.
Led by co-founder and Chief Executive Officer Jürg Camblong, SOPHiA GENETICS is guided by a leadership team that combines expertise in bioinformatics, artificial intelligence and clinical practice. The company went public on the Nasdaq Global Market in February 2021, positioning itself to accelerate platform development and extend its presence in rapidly evolving markets for genomics and medical imaging analytics.
